Bioventus Inc.
For the period ended Jun 28, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 28, 2025 · Filed Aug 6, 2025
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Cash Flows for the
Consolidated Condensed Statements of Cash Flows
Six Months Ended June 28, 2025 and June 29, 2024
(Amounts in thousands)
| Six Months Ended | ||
|---|---|---|
| June 28, 2025 | June 29, 2024 | |
| Operating activities: | ||
| Net income (loss) | $5,950 | $(40,598) |
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation and amortization | 23,914 | 24,875 |
| Provision (benefit) for credit losses | 843 | (537) |
| Equity-based compensation | 6,057 | 8,767 |
| Change in fair value of contingent consideration | — | 595 |
| Deferred income taxes | 87 | (8,098) |
| Impairment of assets | — | 31,870 |
| Loss on disposals | 82 | — |
| Unrealized (gain) loss on foreign currency fluctuations | (365) | 536 |
| Other, net | 763 | 961 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (4,625) | (21,933) |
| Inventories | (4,690) | (8,359) |
| Accounts payable and accrued expenses | (22,681) | 22,552 |
| Other current and noncurrent assets and liabilities | 1,272 | (1,474) |
| Net cash from operating activities | 6,607 | 9,157 |
| Investing activities: | ||
| Settlement from the sale of a business | (686) | — |
| Purchase of property and equipment | (1,509) | (368) |
| Investments and acquisition of distribution rights | — | (709) |
| Net cash from investing activities | (2,195) | (1,077) |
| Financing activities: | ||
| Proceeds from issuance of Class A common stock | 1,467 | 786 |
| Payment of contingent consideration | (19,771) | — |
| Borrowing on revolver | 15,000 | — |
| Payment on revolver | (10,000) | — |
| Debt refinancing costs | — | (1,180) |
| Payments on long-term debt | — | (11,320) |
| Other, net | (412) | (373) |
| Net cash from financing activities | (13,716) | (12,087) |
| Effect of exchange rate changes on cash | 632 | (963) |
| Net change in cash and cash equivalents | (8,672) | (4,970) |
| Cash and cash equivalents at the beginning of the period | 41,582 | 36,964 |
| Cash and cash equivalents at the end of the period | $32,910 | $31,994 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Accounts payable for purchase of property, plant and equipment | $196 | $205 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.